Funding profile · Consumer digital health

Reframe

One Form D on record, filed in January 2022 under the company’s original name, reporting $17.45 million sold to 31 investors. Nothing has been filed since, while reported totals have climbed to $24.7 million and $27 million.

$17.45MSold on the only Form D on record, including converted SAFEs
$12.5MSeries A as announced, at a $100M post money valuation
31Investors on that filing, about $563,000 each
$27MTotal raised, company-reported via Forbes, versus $24.7M via Crunchbase

Data as of September 22, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
2018 Accelerator pre-seed $20,000 Georgia Tech CREATE-X University report
2018 to 2020 Founder and family money $120,000 Founders and family University report
By Apr 2021 Seed $1.4M Atlanta Ventures Reporting
Summer 2021 Y Combinator S21 Not disclosed Y Combinator YC data
After YC, 2021 Post accelerator round $3.4M Not named Reporting
Dec 2021 to Jan 2022 Series A $12.5M announced · $17,450,000 sold on the Form D, SAFE conversions included Goodwater Capital led; Atlanta Ventures, HOF Capital, Pioneer Fund, Christopher Klaus, Atlanta angels, Y Combinator Form D and reporting
Jan 2026 Cumulative, reported $24.7M per Crunchbase; $27M per Forbes Not broken out Totals differ

What the filings show

Glucobit Inc. · Form D · filed Jan 18, 2022

First sale
Dec 31, 2021
Offered
$17,450,000 equity
Sold
$17,450,000 · $0 remaining
Clarification
“The total offering amount and total amount sold includes the conversion of SAFEs.”
Investors
31 · average about $563,000
Minimum accepted
$5,000
Exemption
Rule 506(b)
Industry group
Other Technology
Revenue range
Decline to Disclose
Commissions
$0 sales commissions, $0 finders fees
Related persons
Verdant Pradeep (executive officer, director); Ziyi Gao (executive officer, director)
Signed
Vedant Pradeep, President
Filing
SEC EDGAR, CIK 0001905181, Atlanta, GA, incorporated in Delaware, year of incorporation 2018

Reading the filings

  1. The filing is bigger than the press release, and says why.Reporters were told $12.5 million. The Form D reports $17,450,000 sold, a difference of $4,950,000, and the issuer added a clarification that the totals include converted SAFEs. The two prior rounds on the record, $1.4 million of seed and $3.4 million after Y Combinator, add to $4.8 million. The arithmetic lines up with new money plus old paper converting at the Series A.
  2. Thirty one investors, but not thirty one big cheques.$17,450,000 across 31 investors averages about $563,000 each. That average is inflated by SAFE holders folded into the same total, and the minimum accepted was $5,000, which is angel sized. The filing does not separate new subscribers from converting note holders.
  3. Nothing has been filed in four and a half years.This is the only Form D under the issuer, and an EDGAR full text search returns exactly one document mentioning Glucobit. Reported totals of $24.7 million and $27 million sit $7.25 million to $9.55 million above the $17.45 million on file. A company raising under Section 4(a)(2) files no Form D at all, so the gap is not proof that no money moved, but nothing public closes it.
  4. On paper the issuer is not a health company.The filer is Glucobit Inc., the founders’ original name, still the entity behind the terms of use and the Google Play listing. It selected Other Technology as its industry group rather than any health category, and answered Decline to Disclose on revenue about a month before its founders told reporters that annual recurring revenue had crossed $10 million.
  5. The board is the two founders.The only related persons listed are the co-founders, each as executive officer and director. No investor director appears, despite a lead investor on the round. The CEO’s first name is entered as Verdant rather than Vedant, the same misspelling that later appeared in the company’s own December 2025 press release.
  6. The valuation is reported, never filed.A $100 million post money valuation in January 2022 and a $350 million figure in a later Forbes profile both come from outside the filings. Form D records amounts raised, not price, so neither number has a public document behind it.

Commercial signals

Signal Detail Source type
Revenue About $10 million ARR reported by the CEO in Feb 2022; $13 million booked in 2022 per a Forbes profile. No figure since. Company-stated
Subscribers About 100,000 paying subscribers as of Mar 2022. Not updated publicly since. Company-stated
Pricing $99.99 a year base. Thrive Coaching $129.99 or $249.99 a month, $79.99 a session. AI chat $9.99 a month. Med+ billed in three month blocks. Independent review
New lines Liquid Luck functional drinks, Mar 2025. Reframe Med+ telehealth prescribing with OpenLoop Health, Inc., live by 2026. Company-stated
Regulatory No FDA 510(k) or PMA, no registered trial, no NIH or NSF award. The app is sold as a wellness subscription. Public record
Consumer record Better Business Bureau profile records 9 complaints in three years, two of them unanswered, almost all about billing. Not BBB accredited. Public record
Cancellation exposure Web terms require 30 days notice before renewal and make payments nonrefundable. The Google Play listing says 24 hours. The FTC reopened negative option rulemaking on Mar 11, 2026 and keeps enforcing under ROSCA. Terms disagree

What to watch

  • A Form D for anything raised since January 2022. One is due within 15 days of a first sale under Regulation D.
  • Whether the Med+ prescribing line is housed separately, which would show up as a new issuer on EDGAR.
  • An updated revenue or subscriber figure. The last public numbers are more than four years old.
  • Any FTC or state action on subscription cancellation, given the billing complaints and the conflicting terms.

The Reframe story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • Fitia: Shared investor: Goodwater. A Lima-built AI meal planner and calorie counter that says it has passed 10 million users across the Spanish-speaking world and is now pushing into the United States
  • Farmako Healthcare: Shared investor: Goodwater. A Gurugram startup that pivoted from a digital health records app to 30 minute medicine delivery, now running pharmacies in Gurugram and Moradabad while it works toward
  • DocVita: Shared investor: Goodwater. A WhatsApp led marketplace that matches Indian patients with vetted therapists and psychiatrists, online and in person
  • Joon Health: Shared investor: Goodwater. A gamified app that turns a child’s ADHD, autism or anxiety routines into quests for a virtual pet

Sources

  1. Public recordForm D, Glucobit Inc., CIK 0001905181SEC EDGAR · Jan 18, 2022
  2. Public recordEDGAR full text search and issuer submissions index for Glucobit Inc.SEC · accessed Sep 2026
  3. Public recordFDA, ClinicalTrials.gov, NIH and NSF searches, no resultsSep 2026
  4. Public recordReframe BBB business profile and complaint record, AtlantaBetter Business Bureau · accessed Sep 18, 2026
  5. Public recordReframe: Cut Back on Alcohol, developer Glucobit Inc.Google Play · updated Sep 21, 2026
  6. IndependentThe startup sobriety gambitTechCrunch, Alex Wilhelm · Feb 5, 2022
  7. IndependentApp to moderate drinking raises $12.5 millionFortune · Mar 5, 2022
  8. IndependentEngineering Alumni Create Mobile App to Reduce Alcohol AbuseGeorgia Tech College of Engineering · Apr 19, 2021
  9. IndependentReframe Dry January data storyHypepotamus · Jan 6, 2026
  10. IndependentVedant Pradeep profile, 30 Under 30 Consumer TechnologyForbes
  11. IndependentReframe App Review 2026: Pros & Cons, Cost, & My ExperienceChoosingTherapy.com · updated 2026
  12. IndependentFTC Restarts Negative Option RulemakingGibson Dunn · Feb 27, 2026
  13. CompanyReframe terms of use and FAQjoinreframeapp.com · terms last updated Dec 30, 2023
  14. CompanyReframe Med+ site and terms and conditions of servicesjoinreframemed.com · accessed Sep 2026
  15. CompanyReframe company page, Summer 2021 batch, team size 35Y Combinator · accessed Sep 2026

Compiled from SEC and other public records and published reports as of September 22, 2026. Form D notices report offerings under Regulation D; amounts reflect the filing date and may not capture later sales. Healthcare Venture Capital Fund holds no position in Reframe. This page is not an offer to sell or a recommendation to buy any security.